SEC Form 4 · accession 0000899243-16-023189
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory L. Verdine
Director
Period of report
Jun 16, 2016
Accepted (ET)
Jun 17, 2016 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 15, 2016 | S | 52,000 | $16.70 | D | 150,079 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.70 to $16.76, inclusive. The reporting person undertakes to provide to WAVE Life Sciences Ltd., any security holder of WAVE Life Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.